Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial

Shu Chen Chang, Chee Jen Chang, Yu Jr Lin, Iebin Lian, Cathy S.J. Fann

Research output: Contribution to journalArticle

Abstract

The primary objective of a Phase I cancer clinical trial is to determine the maximum tolerated dose of a drug. The "failure probability" was proposed and used as a constraint to help identify a suitable initial dose range. The maximum tolerated dose was then determined based on a 3 + 3 cohort-based escalation scheme. Multiple simulations were conducted, and the method was evaluated according to the required sample size and accuracy and precision of maximum tolerated dose estimate. The results indicated that the median of the initial dose range suggested using a failure probability is a suitable initial dose regardless of the dose escalation sequence used for a cancer Phase I study. This initial dose required a smaller sample size and resulted in less bias of the estimated maximum tolerated dose compared with a commonly used initial dose, that is, 10% of the lethal dose. We tested our approach using real dose and toxicity outcome data from two published Phase I studies. These results indicate that adding a failure probability constraint into the calculation of the initial dose range will improve the efficiency of Phase I cancer trials.

Original languageEnglish
Pages (from-to)556-562
Number of pages7
JournalJournal of Food and Drug Analysis
Volume22
Issue number4
DOIs
Publication statusPublished - 2014 Dec 1

Fingerprint

Clinical Trials, Phase I
Maximum Tolerated Dose
clinical trials
neoplasms
dosage
Sample Size
Neoplasms
Pharmaceutical Preparations
lethal dose

All Science Journal Classification (ASJC) codes

  • Food Science
  • Pharmacology

Cite this

Chang, Shu Chen ; Chang, Chee Jen ; Lin, Yu Jr ; Lian, Iebin ; Fann, Cathy S.J. / Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial. In: Journal of Food and Drug Analysis. 2014 ; Vol. 22, No. 4. pp. 556-562.
@article{0f39862ce14f4c49bd65b427468608b4,
title = "Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial",
abstract = "The primary objective of a Phase I cancer clinical trial is to determine the maximum tolerated dose of a drug. The {"}failure probability{"} was proposed and used as a constraint to help identify a suitable initial dose range. The maximum tolerated dose was then determined based on a 3 + 3 cohort-based escalation scheme. Multiple simulations were conducted, and the method was evaluated according to the required sample size and accuracy and precision of maximum tolerated dose estimate. The results indicated that the median of the initial dose range suggested using a failure probability is a suitable initial dose regardless of the dose escalation sequence used for a cancer Phase I study. This initial dose required a smaller sample size and resulted in less bias of the estimated maximum tolerated dose compared with a commonly used initial dose, that is, 10{\%} of the lethal dose. We tested our approach using real dose and toxicity outcome data from two published Phase I studies. These results indicate that adding a failure probability constraint into the calculation of the initial dose range will improve the efficiency of Phase I cancer trials.",
author = "Chang, {Shu Chen} and Chang, {Chee Jen} and Lin, {Yu Jr} and Iebin Lian and Fann, {Cathy S.J.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.jfda.2013.12.004",
language = "English",
volume = "22",
pages = "556--562",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "National Laboratories of Foods and Drugs",
number = "4",

}

Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial. / Chang, Shu Chen; Chang, Chee Jen; Lin, Yu Jr; Lian, Iebin; Fann, Cathy S.J.

In: Journal of Food and Drug Analysis, Vol. 22, No. 4, 01.12.2014, p. 556-562.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of a failure probability constraint to suggest an initial dose in a phase I cancer clinical trial

AU - Chang, Shu Chen

AU - Chang, Chee Jen

AU - Lin, Yu Jr

AU - Lian, Iebin

AU - Fann, Cathy S.J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - The primary objective of a Phase I cancer clinical trial is to determine the maximum tolerated dose of a drug. The "failure probability" was proposed and used as a constraint to help identify a suitable initial dose range. The maximum tolerated dose was then determined based on a 3 + 3 cohort-based escalation scheme. Multiple simulations were conducted, and the method was evaluated according to the required sample size and accuracy and precision of maximum tolerated dose estimate. The results indicated that the median of the initial dose range suggested using a failure probability is a suitable initial dose regardless of the dose escalation sequence used for a cancer Phase I study. This initial dose required a smaller sample size and resulted in less bias of the estimated maximum tolerated dose compared with a commonly used initial dose, that is, 10% of the lethal dose. We tested our approach using real dose and toxicity outcome data from two published Phase I studies. These results indicate that adding a failure probability constraint into the calculation of the initial dose range will improve the efficiency of Phase I cancer trials.

AB - The primary objective of a Phase I cancer clinical trial is to determine the maximum tolerated dose of a drug. The "failure probability" was proposed and used as a constraint to help identify a suitable initial dose range. The maximum tolerated dose was then determined based on a 3 + 3 cohort-based escalation scheme. Multiple simulations were conducted, and the method was evaluated according to the required sample size and accuracy and precision of maximum tolerated dose estimate. The results indicated that the median of the initial dose range suggested using a failure probability is a suitable initial dose regardless of the dose escalation sequence used for a cancer Phase I study. This initial dose required a smaller sample size and resulted in less bias of the estimated maximum tolerated dose compared with a commonly used initial dose, that is, 10% of the lethal dose. We tested our approach using real dose and toxicity outcome data from two published Phase I studies. These results indicate that adding a failure probability constraint into the calculation of the initial dose range will improve the efficiency of Phase I cancer trials.

UR - http://www.scopus.com/inward/record.url?scp=84916940070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916940070&partnerID=8YFLogxK

U2 - 10.1016/j.jfda.2013.12.004

DO - 10.1016/j.jfda.2013.12.004

M3 - Article

AN - SCOPUS:84916940070

VL - 22

SP - 556

EP - 562

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 4

ER -